Delivery Order SPE2DB20D1047-SPE2DB25FF74G
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Oxcarbazepine ER 600 mg tablets (100-count) on August 7, 2025, with a ceiling value of $12,813.16. This firm fixed price delivery order, which represents non-competitive procurement, is scheduled for completion by August 8, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and was competitively awarded under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Oxcarbazepine ER 600 mg tablets in quantities of 100 units, with a ceiling value of $3,449.47 and firm fixed pricing. This delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by August 1, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a continuation of the vendor's established...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Oxcarbazepine ER 600 mg tablets (100-count packaging) under a firm fixed-price contract valued at $7,215.32. The award, which must be completed by September 18, 2025, represents a competitive procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The U.S. Defense Department's Medical Supply Chain awarded a $4,923.54 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Oxcarbazepine ER 600 mg tablets (100-count units). This firm fixed-price, non-set-aside contract is scheduled for ultimate completion by July 28, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under a larger contract vehicle,...
- The Defense Logistics Agency awarded a $2,043.54 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Oxcarbazepine ER 600 mg tablets in quantities of 100 units. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of July 9, 2025, with performance taking place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value pharmaceutical transaction...
- The Defense Logistics Agency awarded a $34.77K firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Oxcarbazepine ER 600 mg tablets (100-count units) with an ultimate completion date of May 13, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor, with performance taking place at the company's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,736.37 to AmerisourceBergen Drug Corp for Oxcarbazepine 300 mg/5 mL suspension in 250 mL quantities. The contract, executed on June 18, 2025, with an ultimate completion date of June 20, 2025, utilizes firm fixed price terms with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger federal...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,008.18 firm fixed-price delivery order on August 25, 2025, for Oxcarbazepine 300 mg/5 ml suspension in a 250 ml container. This is a non-set-aside contract with an ultimate completion date of August 26, 2025, and performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $1,958.79 to AmerisourceBergen Drug Corp for the supply of Oxcarbazepine 300 mg/5 mL suspension in 250 mL quantities. The contract is a firm fixed price delivery order with no set-aside designation, competitively awarded on September 3, 2025, with an ultimate completion date of September 4, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This is a federal contract award made by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,048.26, is for the delivery of 100 tablets of Oxcarbazepine ER 150 mg, a medication used to treat seizures. This is a Firm Fixed Price Delivery Order contract, with an ultimate completion date of January 24, 2025. The contract was awarded on January 23, 2025, and was not...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF74GDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Oxcarbazepine ER 150 mg tablets (100-count units) with a ceiling value of $2,169.26. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this qualified vendor. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime contractor, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Oxcarbazepine supply supports military healthcare programs requiring this neurological treatment medication. AmerisourceBergen Drug Corp's role as a pharmaceutical prime vendor demonstrates its capability to fulfill diverse federal medical supply requirements across multiple therapeutic domains through open competition. Performance is scheduled for completion by July 28, 2025, at the company's Conshohocken, Pennsylvania location.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 7/25/25 |